Overview

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2031-01-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Cladribine
ruxolitinib
venetoclax